Ann and Sol Schreiber Mentored Investigator Award
The Ann and Sol Schreiber Mentored Investigator Award provides funding for trainees (post-doctoral fellows or clinical fellows) who are working under the supervision of a mentor who is a recognized leader in the field of ovarian cancer research. Applicants must have an MD or a PhD degree. The award provides a total of $75,000 to be used over one or two years, and will encourage the recipient’s research career in the field of ovarian cancer. This grant is named in honor of Ann and Sol Schreiber, OCRA’s founders.
2021 Grant Recipients
-
Anup Singh, PhD,
La Jolla Institute for Immunology
Studying the Role of BRCA1 in Regulating Heterochromatin Structure and Function in Ovarian Cancer
-
Melanie Weigert, PhD,
University of Chicago
Genome-Wide Profiling of 5-hydroxymethylcytosine on Cell-Free DNA
-
Anne M. van Harten, PhD,
Thomas Jefferson University
Targeted MDM2 Degradation as a Novel Treatment for Ovarian Cancer
-
Bojana Stefanovska, PhD,
University of Minnesota Twin Cities
APOBEC3B and DNA Repair as Synthetic Lethal Combinations in CCOC
-
Sammy Ferri-Borgogno, PhD,
MD Anderson Cancer Center
Spatially-Resolved Cellular and Transcriptome Analyses of Ovarian Cancer
-
Sridevi Challa, PhD,
UT Southwestern Medical Center
Role of Ribosomal Protein Mono(ADP-ribosyl)ation in Protein Quality Control
-
Benoît Bragantini, PhD,
Mayo Clinic
Probing Homologous Recombination DNA Repair Factors in Chromatin by cryo-EM
-
Ronja Anugwom, PhD,
MD Anderson Cancer Center
Determine Resistance Mechanisms to ATR Inhibition in Ovarian Cancers
-
Wei Zhou, PhD,
The Wistar Institute
Targeting the mevalonate pathway in ARID1A-mutated ovarian cancer
-
Xueyang Yu, PhD,
Massachusetts Institute of Technology
Macrophage Control of the Microenvironment Drives HGSOC Progression
2020 Grant Recipients
-
David Chapel, MD,
Brigham and Women’s Hospital
The Migratory Precursor and Serous Carcinogenesis
-
Yilun Deng, PhD,
University of Texas Health Science Center at San Antonio
CD122-Selective IL-2 Complexes as Novel Ovarian Cancer Therapy
-
Elizabeth Lee, MD,
Dana Farber Cancer Institute
Phase II Trial of Gemcitabine+ATR Inhibitor: Translational Studies
-
Jianhuang Lin, PhD,
The Wistar Institute
Targeting ER Stress Pathway in CARM1-Expressing Ovarian Cancer
-
Duygu Ozmadenci, PhD,
University of California - San Diego
Sensitizing Ovarian Cancer to Immunotherapies
-
Elizabeth Raupach, PhD,
The Translational Genomics Research Institute
Oncogenic Consequences of Altered SWI/SNF-RNA Interactions in SCCOHT
-
Camilla Salvagno, PhD,
Weill Medical College of Cornell University
Dissecting How ER Stress Responses Shape Ovarian Cancer Immuno-Environments
-
Janice Santiago, PhD,
MD Anderson Cancer Center
Crizotinib Improves the Therapeutic Efficacy of Olaparib in Ovarian Cancer
-
Ignacio Vázquez-García, PhD,
Memorial Sloan Kettering Cancer Center
Co-Evolution and Dynamics of Malignant and Immune Cells in Ovarian Cancer
-
Morozov Yaroslav, PhD,
University of Pennsylvania
The BRCA1-A as a Determinant of Chemotherapy Response in ATM Mutated Cells
2019 Grant Recipients
-
Kristin G. Anderson, PhD,
Fred Hutchinson Cancer Research Center
Engineering Adoptive T Cell Therapy for Efficacy in Ovarian Cancer
-
Alexander Cole, PhD,
Magee-Womens Research Institute
Investigating Regulators of Quiescence in Epithelial Ovarian Cancer
-
Sarah Gitto, PhD,
University of Pennsylvania
Modeling Autologous TIL Therapy in Novel PARP Resistant PDX Model for Ovarian Cancer
-
Guy Katz, MD, PhD,
MD Anderson Cancer Center
Therapeutic miRNA Targeting for Ovarian Cancer
-
Isaac Klein, MD, PhD,
Dana Farber Cancer Institute
Transcriptional Regulatory Landscape of High Grade Serous Ovarian Cancer
-
John Krais, PhD,
Fox Chase Cancer Center
Examining the Role of RNF168 in BRCA1 Mutant Ovarian Cancer
-
Marilyne Labrie, PhD,
Oregon Health and Science University
Synergistic Lethality of PARP and P13K Pathway Inhibitors in Ovarian Cancer
-
Jing Li, MD, PhD,
University of Michigan
ARID1A Drives Ovarian Cancer Immunotherapy
-
Shariska Petersen, MD,
University of Kansas Medical Center Research Institute
Cyclin E and BRD4 as Markers for a New PARPi Drug Combination
-
Alba Rodriguez-Garcia, PhD,
University of Pennsylvania
Targeting MISIIR with CAR T Cells for the Treatment of Ovarian Cancer
-
Elaine Stur, PhD,
MD Anderson Cancer Center
Re-activating Anti-tumor Immunity Targeting PSEN1 in CAFS in Ovarian Cancer
-
Shuai Wu, PhD,
The Wistar Institute
Synthetic Lethality for ARID1A Mutation in Ovarian Cancer
-
Haineng Xu, PhD,
University of Pennsylvania
A Novel Targeted Therapy for Cyclin E Over Expressing Ovarian Cancers
-
Zvi Yaari, PhD,
Memorial Sloan Kettering Cancer Center
Implantable Nanosensor for Early-Stage Detection of Ovarian Cancer
2018 Grant Recipients
-
Damayanti Chakraborty, PhD,
Massachusetts General Hospital
Understanding Epigenetic Regulation of Copy Number Gains in Ovarian Cancer
-
Daniele Chaves-Moreira, PhD,
The University of Pennsylvania
Isolation and Characterization of the PAX8 Transcriptional Complex
-
Chin-Chi Chen, PhD,
Johns Hopkins University
Determining the Role of ARID1A in 53BP1-mediated DNA Damage Repair
-
Shih-Hsun Chen, PhD,
Beckman Research Institute of the City of Hope
Targeting de-poly (ADP-ribosyl)ation for Ovarian Cancer Therapy
-
Matthew Dean, PhD,
The University of Illinois at Chicago
The Ovarian Microenvironment in Metastasis of Fallopian Tube Derived Cancer
-
Marcela Haro, PhD,
Cedars-Sinai Medical Center
Cancer Associated Fibroblasts Hinder the B Cell Anti-Tumor Response
-
Ye Hu, MD, PhD,
Cedars-Sinai Medical Center
Reciprocal Roles of CAFs and CD4+ T Cells in Cancer Progression
-
Justyna Kanska, PhD,
Cedars-Sinai Medical Center
Identifying Synthetic Lethal Targets to Mutant p53 in Development of HGSOC
-
Goldie Lui, PhD,
Fred Hutchinson Cancer Research Center
Identifying Novel Targeted Therapies for MYC-driven Ovarian Cancer
-
Sarah Stuckelberger, MD,
The University of Pennsylvania
Development of A Novel Syngeneic Model System for Ovarian Cancer Research
-
Yinu Wang, PhD,
Northwestern University
Characterization of Chromatin Nanoarchitecture of Ovarian Cancer Stem Cells
-
Shuang Zhang, PhD,
New York University School of Medicine
Modeling Human HGSOC Using Fallopian Tube Organoid Cultures
2017 Grant Recipients
-
Nabanita Chatterjee, PhD,
MD Anderson Cancer Center
Ovarian Cancer Disrupts Circadian Cortisol Rhythms
-
Marion Curtis, PhD,
University of Chicago
Mediators of Chemosensitivity and Immunotherapy Targets
-
Anniina Farkkila, MD, PhD,
Dana Farber Cancer Institute
Overcoming PARP Inhibitor Resistance in Ovarian Cancer
-
Jagmohan Hooda, PhD,
University of Pennsylvania
Loss of H2Bub1 Rewires Glutamine Metabolism During Progression of HGSOC
-
Gilbert Huang, PhD,
MD Anderson Cancer Center
Targeting Dormant Ovarian Cancer Cells with Peptide Inhibitors of Autophagy
-
Dongyu Jia, PhD,
Cedars-Sinai Medical Center
COL11A Is A Highly Specific Therapeutic Target in Cancer-Activated Stroma
-
Venkatesh Krishnan, PhD,
Stanford University
Omental Macrophages: Drivers of Ovarian Cancer Metastasis
-
Xianzhi Lin, PhD,
Cedars-Sinai Medical Center
Systematic Discovery of LncRNA Interactome in Epithelial Ovarian Cancer
-
Beatrice Rondinelli, PhD,
Dana Farber Cancer Institute
EZH2 Determines PARPi Resistance and Fork Stabilization in Ovarian Tumors
-
Priyanka Verma, PhD,
University of Pennsylvania
BRCA-Independent DNA Repair Pathways in Ovarian Cancer
2016 Grant Recipients
-
Jessica Chacon, PhD,
University of Pennsylvania
Investigating the Role of Immunosuppressive Molecules in Ovarian Cancer
-
Song Yi Ko, PhD,
MD Anderson Cancer Center
A “Trojan Horse” Mechanism That Mediates Resistance to Anti-VEGF Therapy
-
Jill Madden, PhD,
Inc., University of Kansas Medical Center Research Institute
The Effect of FoxM1 Inhibition on Ovarian Cancer Immunity and Sensitivity
-
Abir Mukherjee, PhD,
University of Chicago
Microenvironment Mediated Stabilization of Hif-1 Alpha in Ovarian Cancer
-
Debarshi Roy, PhD,
Mayo Clinic
Crosstalk Between Glycolytic Pathway Inhibition and Increased Autophagy
-
Qian Tan, MD, PhD,
Stanford University
Activation of Macrophages by Inhibiting CD47 Signaling in Ovarian Cancers
-
Ryan Williams, PhD,
Memorial Sloan Kettering Cancer Center
An Ovarian Cancer Biosensor for Rapid, Non-invasive Disease Detection
-
Nur Yucer, PhD,
Cedars-Sinai Medical Center
Modeling Mullarian HGSC Using BRCA1 Patient Derived iPSCs
-
Fan Zhao, PhD,
Stanford University
Ovarian Cancer Antigen Discovery by Single t-cell Analysis and pHLA Library
-
Hengrui Zhu, PhD,
The Wistar Institute
Epigenetic Targeting of Cancer Stem-like Cells (CSCs) in Ovarian Cancer
2015 Grant Recipients
-
Juan Cubillos-Ruiz, PhD,
Weill Medical College of Cornell University
ER Stress Sensor XBP1 as a Key Regulator of Ovarian Cancer Immunity
-
Justyna Filant, PhD,
MD Anderson Cancer Center
Novel Extra Cellular RNA-based Combinatorial RNA Inhibition Therapy
-
Xiaowen Hu, PhD,
University of Pennsylvania
Long Non-coding RNAs in Epithelia Ovarian Cancer
-
Petar Jelinic, PhD,
Memorial Sloan Kettering Cancer Center
EMSY Suppresses HDR in a BRCA2-interaction-independent Manner
-
Zeina Kais, PhD,
Dana Farber Cancer Institute
Synthetic Lethality Between CCNE1 Amplification and USP1 Inhibition
-
Bob McGray, PhD,
Roswell Park Cancer Institute
Combination Oncolytic Virotherapy/ACT for Ovarian Cancer Treatment
-
Alfredo Perales-Puchalt, MD,
The Wistar Institute
Targeting FSH Receptor with Chimeric Antigen Receptor in Ovarian Cancer
-
Nicole Spardy, PhD,
Dana Farber Cancer Institute
Identification of New Genetic Dependencies in HR-deficient Ovarian Cancers
-
Wei Wei, PhD,
Massachusetts General Hospital
Genomic Analysis to Predict Recurrence in Early Stage Ovarian Cancer
-
Oladapo Yeku, MD, PhD,
Memorial Sloan Kettering Cancer Center
A Phase I Trial Using Chimeric Antigen Receptors in Ovarian Cancer Patients
2014 Grant Recipients
-
Nima Aghaeepour, PhD,
Stanford University
Computationally-guided Characterization of Therapy-resistant Ovarian Tumors
-
Raphael Ceccaldi, PharmD, PhD,
Dana Farber Cancer Institute
A Bioinformatic Screen Identifies POLQ Overexpression in Ovarian Cancers
-
Ilana Chefetz, PhD,
University of Michigan
A Role for ALDH in the Regulation of Necroptosis in Ovarian Cancer Area of research: Therapeutic Targeting
-
Ellen Cheon, PhD,
Cedars-Sinai Medical Center
Collagen-Remodeling Genes Provide a Niche for Ovarian Cancer
-
Laura Dillon, PhD,
University of Virginia
Differential MicroDNA Generation in Ovarian Cancer
-
Mo Li, PhD,
University of Michigan
Mechanism of PARP Inhibitor in Ovarian Cancer Therapy Cancer
-
Kyung Hee Noh, PhD,
MD Anderson Cancer Center
Targeting Adaptive Changes to anti-VEGF Therapy in Ovarian Cancer
-
Shailja Pathania, PhD,
Dana Farber Cancer Institute
Novel Therapeutic Targets for High-Grade Serous Ovarian Carcinoma
-
Megan Rice, ScD,
Brigham and Women’s Hospital
Dietary Fat, Cholesterol, and Ovarian Cancer Risk
-
Yang Yang, PhD,
Yale University
P53 Aggregation: a New Target to Combat Ovarian Cancer Platinum-Resistance
-
Chi Lam Au Yeung, PhD,
MD Anderson Cancer Center
Adipose Tissue Derived Exosomal miRNAs in Ovarian Cancer Progression
-
Yuyu Yuyu, PhD,
Johns Hopkins University School of Medicine
Targeting Spleen Tyrosine Kinase in Chemoresistant Ovarian Cancer
2013 Grant Recipients
-
Pradeep Chaluvally-Raghavan, PhD,
MD Anderson Cancer Center
Role of microRNAs in the 3q26 Amplicon in Ovarian Cancer Pathophysiology and Therapy
-
Ronald Chandler, PhD,
University of North Carolina - Chapel Hill
A Genetically Relevant Mutant Mouse Model of Epithelial Ovarian Cancer
-
Diana Hargreaves, PhD,
Stanford University
Targeting Ovarian Cancer via Cooperative Oncogene Interactions
-
Christine Lawson, PhD,
University of California - San Diego
Testing the FAK and Talin Signaling Linkage in Ovarian Tumor Cell Metastasis
-
Teng Ma, MD, PhD,
University of Michigan - Ann Arbor
The Analysis of NEDD8-activating Enzyme Inhibitor MLN4924 on Ovarian Cancer
-
David Pepin, PhD,
Massachusetts General Hospital
Mechanisms and Markers to Target a Stem Enriched Population of Primary Ovarian Cancer Ascites with the Müllerian Inhibiting Substance
-
Yin Wang, PhD,
Mayo Clinic Jacksonville
Protein Kinase C iota is a Novel Therapeutic Target for Ovarian Cancer Treatment
2012 Grant Recipients
-
Bin Guan, PhD,
Johns Hopkins University School of Medicine
Functional Characterization of the Tumor Suppressor ARID1A in Ovarian Cancer
-
Kate Lawrenson, PhD,
University of Southern California
Modeling Stem Cell Origins of Epithelial Ovarian Carcinomas
-
Hanqing Liu, PhD,
Fox Chase Cancer Center
Targeting Signaling Networks via RNAi to Improve Therapy for Ovarian Cancer
-
Ngai Na Co, PhD,
MD Anderson Cancer Center
The Role of Stromal microRNA 21 in Omental Ovarian Cancer Progression
-
See-Hyoung Park, PhD,
Stanford University
Targeting Ovarian Cancer with Combination of Olaparib and Bepridil
-
Melinda Yates, PhD,
MD Anderson Cancer Center
Unraveling the Initiation of Ovarian Cancer: The BRCA1-Heterozygous Mouse as a Model System
2011 Grant Recipients
-
Anirban Mitra, PhD,
University of Chicago
How Do Cells Near Ovarian Cancer Cells Play a Role in the Disease?
-
Gregory Motz, PhD,
University of Pennsylvania
Stimulating Immune Cells to Fight Ovarian Cancer
-
Ruth Perets, MD, PhD,
Dana Farber Cancer Institute
Trying to Identify the Cell Responsible for Ovarian Cancer
-
Sharmistha Sarkar, PhD,
MD Anderson Cancer Center
Finding a Marker to Detect Early Stage Ovarian Cancer
-
Sherry Wu, PhD,
MD Anderson Cancer Center
Novel Approach to Destroy the Blood Supply that Feeds Ovarian Cancer Tumors
-
Tsz-Lun Yeung, PhD,
MD Anderson Cancer Center
Understanding How Ovarian Cancer Spreads
2008 Grant Recipients
-
Weiwei Shan, PhD,
MD Anderson Cancer Center
Cellular Microenvironment Role in Ovarian Cancer Development
-
Takayo Ota, MD, PhD,
Mayo Clinic Rochester
Characterizing the Genetic Alterations of Aggressive Ovarian Cancer
-
Xiaoping He, MD, PhD,
Mayo Clinic Rochester
Understanding the Molecular Pathways to Chemotherapy Resistance in Ovarian Cancer
-
Thuy-Vy Do, PhD,
Fox Chase Cancer Center
Understanding How Ovarian Cancer Spreads
-
Lejla Delic, MD,
Cedars-Sinai Medical Center
A New Class of Drugs with Potential Against Ovarian Cancer: PARP-inhibitors
2007 Grant Recipients
-
Hong Zhang, PhD,
Fox Chase Cancer Center
Novel Animal Model to Test Drugs Against Ovarian Cancer
-
Melissa Merritt, PhD,
Brigham and Women’s Hospital
How Might Different Tissues in the Ovary Act on Each Other to Induce Cancer
-
Mitchell Cheung, PhD,
Fox Chase Cancer Center
Testing New Therapeutic Agents to Treat Ovarian Cancer
-
Kuang-Hung Cheng, PhD,
Brigham and Women’s Hospital
Animal Model to Study Ovarian Cancer Stem Cells
2006 Grant Recipients
-
Ramandeep Rattan, PhD,
Mayo Clinic
Gene May Be an Early Marker for Ovarian Cancer
-
Andres Matoso, MD,
Cornell University
An Animal Model to Study Major Genetic Alterations in Ovarian Cancer
-
Aliza Leiser, MD,
Yale University
Clinical Implications of the TLR-4MYD88 Pathway in EOC
-
Audrey Gagnon, PhD,
Brigham and Women’s Hospital
New Analytical Tool for Ovarian Cancer Detection
-
Adam Clauss, PhD,
Dana Farber Cancer Institute
Does Ovarian Cancer Originate in the Fallopian Tube?
-
Maria Barbolina, PhD,
University of Illinois - Chicago
Epigenetic Regulation of Metastasis-Associated Gene Expression in EOC
-
Tsukasa Baba,
Duke University
Using Public Resources to Find New Drugs to Treat Resistant Ovarian Cancer
2005 Grant Recipients
-
Deyin Xing, MD, PhD,
Massachusetts General Hospital
Models to Study Hereditary Ovarian Cancer
-
Jason Wilken, PhD,
Yale University
Making an Antibody Treatment for Breast Cancer Work for Ovarian Cancer
-
Ritu Salani, MD,
Johns Hopkins University School of Medicine
DNA Fragments Might be a Way to Screen for Ovarian Cancer
-
Joseph Kwong, PhD,
Brigham and Women’s Hospital
Could Inflammation of Ovarian Cells be the Cause of Ovarian Cancer?
-
Amy BonDurant, MD,
Duke University
Chemical Changes on DNA May Be a Way to Screen for Ovarian Cancer and its Recurrence
-
Donna Badgewell, PhD,
MD Anderson Cancer Center
Developing a Screening Test for Ovarian Cancer
2004 Grant Recipients
-
Xiaoyan Ni, PhD,
Brigham and Women’s Hospital
Biomarkers for Ovarian Cancer
-
Brian Barnett, MD,
Tulane University Health Sciences Center
Depleting Regulatory T Cells to Treat Ovarian Cancer
2003 Grant Recipients
-
Monique Spillman, MD, PhD,
Duke University Medical Center
Role of MAP2K4 Suppressing Metastasis of Serous Ovarian Cancers
-
Naomi Hunder, MD,
Fred Hutchinson Cancer Research Center
Evaluation of Mesothelin as a Taret Antigen in Ovarian Cancer
-
Kuan-Chun Huang, PhD,
Brigham and Women’s Hospital
A Possible New Marker for Drug Resistance of Ovarian Cancer
-
Jeremy Chien, PhD,
Mayo Clinic
How Cell Shape Changes Lead to Metastasis in Ovarian Cancer